|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RED CELLS
From the Hemato-Oncology Unit, Hôpital
Universitaire des Enfants Reine Fabiola; the Department of Pediatric
Hematology, Cliniques Universitaires St Luc; and the Department of
Hematology, Hôpital Erasme, Brussels, Belgium; Service de
Pédiatrie, Clinique de l'Espérance, Montegnée,
Belgium; Service de Pédiatrie, Hôpital de la
Citadelle, Liège, Belgium; Kliniek voor Kinderziekten,
Universitair Ziekenhuis, Ghent, Belgium; and UZ Gasthuisberg, Leuven,
Belgium.
The short-term beneficial effect of hydroxyurea (HU) in sickle cell
disease (SCD) has been proven by randomized studies in children and
adults. The Belgian registry of HU-treated SCD patients was created to
evaluate its long-term efficacy and toxicity. The median follow-up of
the 93 patients registered is 3.5 years; clinical and laboratory data
have been obtained for 82 patients at 1 year, 61 at 2 years, 44 at 3 years, 33 at 4 years, and 22 after 5 years. On HU, the number of
hospitalizations and days hospitalized dropped significantly. Analysis
of the 22 patients with a minimum of 5 years of follow-up confirm a
significant difference in the number of hospitalizations
(P = .0002) and days in the hospital
(P < .01), throughout the treatment when compared to
prior to HU therapy. The probabilities of not experiencing any event or
any vaso-occlusive crisis requiring hospitalization during the 5 years
of treatment were, respectively, 47% and 55%. On HU, the rate per 100 patient-years of severe events was estimated to be 3.5% for acute
chest syndrome, 1.2% for aplastic crisis, 0.4% for splenic
sequestration; it was 0% for the 9 patients with a history of stroke
or transient ischemic attack followed for an average of 4 years. No
important adverse effect occurred. Long-term chronic treatment with HU
for patients with SCD appears feasible, effective, and devoid of any
major toxicity; in patients with a history of stroke, HU may be a valid alternative to chronic transfusion support.
(Blood. 2001;97:3628-3632) Severe sickle cell disease (SCD) remains associated
with high morbidity and early mortality.1-3 Patients with
2 or more painful crises per year, stroke, or acute chest syndrome
(ACS) have a reduced life expectancy.3 It has been
estimated that the median age of death for men and women with SCD is,
respectively, 42 years and 48 years. In addition, a high morbidity rate
is related to vascular complications that induce multiple chronic organ
damage affecting the brain, heart, kidneys, liver, eyes, skin,
skeleton, and lungs.4,5 Until recently, no drug therapy
has been able to modify the course of the disease.
In 1994, Charache and coworkers published the results of the
Multicenter Study of Hydroxyurea (MSH) in sickle cell anemia, a
prospective, double-blind, randomized trial with hydroxyurea (HU).6 Significant clinical improvement was observed in
adult patients treated with the drug, when compared to those receiving placebo. Patients receiving HU had lower crises rates, needed fewer
transfusions, and developed ACS less often.6,7
In 1996, we published the results of a pediatric randomized, crossover
pilot study, which confirmed the clear benefit of HU in reducing the
rate of hospitalization and the number of days hospitalized in this
population.8 Although it may be a common practice
currently to treat symptomatic patients with SCD with HU, unanswered
questions remain concerning the long-term effects of this treatment,
especially its sustained efficacy and toxicity.9 Based on
the preliminary but promising observations, it was decided to propose
HU treatment to all highly symptomatic patients and to evaluate their
outcome under treatment.
For these reasons, it was decided to create, under the auspices of the
Belgium Society of Hematology, a national registry of HU-treated SCD
patients (children and young adults) under the responsibility of one of
us (A.F.). This study reports the first 5 years of experience of this registry.
Patients
To be eligible for HU therapy, patients had to fulfill at least one of
the following inclusion criteria: 2 or more vaso-occlusive crises
(VOCs) per year requiring hospitalization defined as painful episodes
probably of vascular origin (trivial causes excluded); one episode of
previous ACS defined as acute chest pain with new lung infiltration and
with PaO2 less than 75 mm Hg; overt
stroke or transient ischemic attack (TIA), defined as transient
neurologic deficit (or seizures) and confirmed by a neurologist after
electroencephalography and imaging; priapism defined as persistent
painful erection not associated with erotic stimulation; or the
development of ischemic bone necrosis, defined as hip or shoulder pain
with functional impairment with abnormal bone scintigraphy, magnetic
resonance imaging, or abnormal radiography. At inclusion (start of HU
therapy), the following minimal information was required: birth date,
country of origin, electrophoretic diagnosis, hemoglobin (Hb) level,
percentage of fetal hemoglobin (HbF), mean corpuscular volume (MCV),
neutrophil counts, previous major adverse events, and number of
hospitalizations and days in the hospital during the last 12 months
before start of HU. All participants agreed to complete, before and
each year after inclusion of their patients, a pre-established registry file. Oral or written consent for HU treatment was obtained for each
patient. The registry was approved and conducted under the auspices of
the Belgian Society of Paediatric Haemato/Oncology and the Belgian
Society of Haematology. The pre-HU data were based on the actual
experience at the clinical centers or on records obtained from other
Belgian centers.
Patients and parents (or legal guardian) were aware of the potential
risks and side effects related to HU. Adults and adolescents were also
aware of the need for active contraception.
The initial dose of HU was 20 mg/kg daily; it was increased by 5 mg/kg if judged appropriate by the treating clinician. Treatment attitude was mainly based on the clinical response of each patient at
the starting dose of 20 mg/kg. There were no fixed guidelines for dose
escalation and dose modification as long as the patient was found to be
adequately controlled by each center's physician. There has never been
any attempt to reach a "maximal tolerated dose." All SCD patients,
whether on HU or other type of treatment, were routinely seen every 2 months. In addition, patients on HU were tested for hematologic
toxicity and HbF response every 2 months.
Annual clinical and biologic evaluation included the following: (1)
status of the patient (alive or dead); (2) number of hospitalizations and days hospitalized each year (for whatever reason); (3) major SCD-related events (such as stroke or TIA, ACS, osteonecrosis, priapism, VOC); (4) transfusions given; (5) presence of hematologic toxicity defined by platelet count less than 100 × 109/L
or white blood cell (WBC) count less than 3 × 109/L; (6)
presence of an opportunistic infection; (7) development of malignant
disease; and (8) other major events.
The annual biologic evaluation was limited to Hb level, HbF, MCV, and
neutrophil count at the end of each year of treatment. Values within 3 months after the last transfusion were not considered. The differential
WBC count was determined using a H3 Blood Cell Count Analyzer (Bayer
Technology, Dublin, Ireland). The dosage of HbF was done by
high-pressure liquid chromatography (HPLC). The mean HU dose per
kilogram was also calculated each year.
Statistical analysis
For the number of hospitalizations, Wilcoxon-signed tests were used to test for differences between mean in successive years. Marginal homogeneity tests (extension of the McNemar test for more than 2 categories) were performed to compare the probability distributions between 2 years. Kaplan-Meier survival curves were estimated for the time to the first VOC and for the time to the first event of any type (stroke, acute chest syndrome, VOC, osteonecrosis alloimmunization, priapism, or hospitalization for any reason). McNemar tests were used to test the equality of VOC rates (or events rates) between 2 different years of treatment. Analyzing only those patients with 5 years of follow-up, a t test was performed to test for a difference in the hematologic results at baseline between patients who had at least one event during their treatment and for patients who had no event during their treatment.
Characteristics of the patients and clinical data Ninety-three patients with severe SCD entered the registry in Belgium. They came from 6 different centers. Among the 91 patients for whom the country of origin is known, 69 (75.8%) came from Congo-Zaire and 6 (6.6%) from Angola. Three patients came from Cameroon, 2 patients each from Burkina-Faso and Mali, and one each from Benin, Ghana, Guinea, India, Nigeria, Uganda, Senegal, Togo, and Turkey. Age at inclusion varied from 8 months to 45 years, with a median of 7 years. Seven children were younger than 2 years at the start of HU treatment, 20 were between 2 and 5 years, 33 were between 5 and 9, 27 were aged 10 to 19 years, and 6 were 20 or older.There were 47 males and 44 females; all except one were homozygous for sickle cell anemia. One patient had SD-Punjab heterozygosity. Before inclusion, 67 (72%) had 2 or more yearly hospitalizations for VOC; 19 (20%) had previous ACS; 17 (18%) a history of osteonecrosis; and 9 (10%) patients presented with stroke or TIA in the previous year. Among the 7 children under 2 years of age, 4 had presented with ACS, 3 had more than 2 VOCs in the 12 months preceding inclusion in the registry, and 3 had recurrent episodes of splenic sequestration; 2 of these 3 last patients had other major criteria, the third one having this sole criteria for registration. Data on hospitalizations during the year preceding inclusion in the registry were obtained from medical records in 78 patients. Fifteen patients fulfilled inclusion criteria but the exact number of hospitalizations or days hospitalized prior to HU was evaluated only on patient recall and thus not considered. The median number of hospitalizations was 2.7 (range, 0-10) and the mean duration in the hospital was 18 days per year per patient (range, 0-82). Among these 93 patients, 82 (88%) were evaluated after 1 year, 61 (66%) after 2 years, 44 (47%) after 3 years, 33 (35%) after 4 years, 22 (24%) after 5 years, and 12 (13%) after 6 years. A total of 254 years of treatment have been assessed ("254 patient-years"). After a median follow-up of 3.5 years, all the patients were still
alive. The median number of hospitalizations dropped from 2 before the
start of HU (with a median duration of hospitalization of 14 d/y) to
zero per year during subsequent years. The mean number of
hospitalizations per year and number of days in the hospital dropped
significantly all along the 5 years of HU treatment (Table
1). SCD-related clinical events on HU are
detailed on Table 2. During the first
year, 84% of patients were free of VOC events requiring
hospitalization. These percentages were 79%, 81%, 90%, and 74%,
respectively, for the second, third, fourth, and fifth year on HU. To
evaluate if HU treatment had any sustained effect, 22 patients who had
a minimum of 5 years of follow-up were analyzed by the Wilcoxon test.
Using this test, a highly significant difference in terms of number of
hospitalizations was observed between the year preceding the start of
HU and the end of the first year of treatment (P = .0002).
In contrast, no significant time effect on the number of
hospitalizations from one year of treatment to the next one or from the
first year of treatment to the last one was observed
(P > .2). The same test applied on all patients available
both at the end of the ith year and the end of the previous year (i-1),
led to the same conclusions.
Considering the number of days hospitalized, no significant change was
demonstrated for patients evaluated after 2 years, 3 years, and 4 years; however, analysis of the 22 patients who were treated for 5 years revealed no difference in the number of days in the hospital at 5 years as compared to baseline values. This might be due to the limited
number of patients evaluated at 5 years because ANOVA did not
demonstrate any time effect all along the study period including the
fifth year (P = .40). Similarly, no significant change was
demonstrated concerning both the occurrence of VOC requiring
hospitalization and the occurrence of any SCD event during the 5 years
of treatment. The McNemar test revealed no significant difference from
one year of treatment to the next one (P
The 9 patients with stroke or TIA remained free of new clinical neurologic complications. Their median follow-up is now 4 years. During the first few months after starting HU some received blood transfusion. Nineteen patients had a history of previous ACS. Eight subsequent episodes were documented on therapy. The overall rate of ACS on HU is estimated at 3.2%/y of treatment. Aseptic necrosis did not occur in any patient with or without a history of bone lesions. No patient developed priapism while on therapy. Two patients developed long-lasting severe hematuria. A diagnosis of papillary necrosis was made and the patients recovered without any renal impairment while continuing HU therapy. Two parvovirus infections with typical aplastic crisis and one splenic sequestration occurred. Forty-two patients have received transfusions during the 254 patient-years. The main reasons for transfusions were continuation of chronic transfusion support for a few months after stroke during the first year on HU (n = 9), ACS (n = 7), surgery (n = 8), aplastic crises (n = 2), or other crises, according to each center's policy (n = 16). One HU- treated patient presented transient hematologic toxicity that resolved after drug dosage was reduced. Neither opportunistic infection nor malignancy has occurred to date. No other major event was reported. Treatment was interrupted in 6 cases. Two patients were successfully grafted with identical HLA siblings and remain free of SCD-related symptoms. One patient remained severely symptomatic with unchanged hospitalization rate and no increase in HbF, despite macrocytosis, and was considered to have failed treatment. Three have abandoned the treatment after few months. At the end of the first year on HU, 55% of patients received HU 20 to 25 mg/kg daily, 41% had a dose under 20 mg/kg per day, and 4% between 25 and 30 mg/kg per day. Only one patient (1.3%) received more than 30 mg/kg per day. These proportions remained unchanged during the subsequent years. Laboratory data At start of HU therapy, the mean Hb level was 8.2 g/dL (range, 5.9-12.3) and mean MCV was 83 fL (range, 60-113). Initial HbF was 7.3% (range, 0.1%-32%). Mean granulocyte count was 6.0 × 109/L (range, 1.9-16).The Hb levels, MCVs, HbF levels, and absolute neutrophil count (ANC)
after each year of therapy are given in Table
3. No relevant change in the hematologic
data occurred from one year of treatment to the next or from the first
year of treatment to the last one. However, a significant difference
was observed between the year preceding the start of HU and the end of
the first year of treatment: higher Hb, higher HbF, higher MCV, and a
low level of polymorphonuclear cells were observed after the first
year of treatment.
A significant change in Hb, MCV, HbF, and ANC was observed after 1 year in the 22 patients who received at least 5 years of treatment. The global time effect tested on these 22 patients who were evaluated for 5 years did not reveal any change in the hematologic results during the 5 years of treatment. Evaluation of these 22 patients did not show any significant difference in the hematologic results at baseline between patients who suffered at least one event during their 5 years of treatment and patients who did not suffer any event during the 5 years.
Allogenic bone marrow transplantation (BMT) remains the only curative therapy in severe SCD.10-12 The last survey of the Belgian experience in BMT for SCD, which included 50 patients, showed an event-free survival of 85% with an overall survival rate of 93%.13 In patients lacking an HLA-identical sibling, refusing the BMT procedure, too old for BMT, or in whom a contraindication exists, HU is the only drug that has been proven to modify the disease at short or middle term,6-8,14 with acceptable toxicity.15 However, the favorable and unfavorable long-term effects of HU, especially in young patients, remain unknown. These questions can only be addressed by establishing large-scale prospective registries or trials. In our prospective registry, patients with severe SCD had markedly milder disease on HU with a significant reduction of the number of hospitalizations or days hospitalized per year, than before they started HU. Our results indicate that the effect of HU has been fairly constant over the 5 years of treatment. Because our conclusions are deduced from registry data and not from a standardized prospective study, there are biases that we have to consider including placebo effect in patients or unconscious bias in physicians taking care of these patients. Furthermore, some heterogeneity may exist between centers in criteria for hospitalization; it is also possible that patients presented themselves to medical care less often because they relied on the drug and it is also possible that physicians admitted the patients less often or kept them in the hospital for fewer days because they trusted the drug. However, the difference between baseline values and values under treatment are important and they can probably not only be explained by these bias. In addition, a 5-year placebo-controlled study would now be considered unethical. The data collected from such a registry give us reliable information concerning the rate of occurrence of sickle cell Hb-related events on therapy, the lack of toxicity of this treatment, the effects on blood parameters, and the overall clinical constancy over years of therapy. Thus clinical improvement observed by many authors in the short term was maintained until the fifth year. Of interest, no patient with previous stroke or TIA had a recurrence, even after arrest of chronic transfusion support, whereas in this population, the relapse rate is usually estimated to be more than 50%16 in patients without transfusion and 13% in those having transfusion.17 Ware and colleagues18 recently reported a cohort of 16 children with SCD and stroke in whom transfusion therapy was stopped and HU started. After a mean follow-up of 22 months, only 3 patients had recurrent strokes, 3 to 4 months after discontinuing transfusion, when HU effects were not maximal. Nevertheless, these very limited data are still insufficient to modify the usual guidelines including chronic transfusions in SCD children with neurologic problems. Only prospective randomized studies will answer the question whether HU is effective for prevention of stroke or TIA. The frequency of ACS was particularly low with 8 episodes for 254 patient-years. In the randomized prospective study of Charache and coworkers (MSH study), 25 episodes6,7 occurred among the 152 patients receiving HU for 2 years or more. The low ACS rate in our population might be due to the fact that the doses at start of HU were higher than in the MSH study and that more stringent criteria for hematologic toxicity requiring drug modification was used in the MSH study. However, the ANC after 2 years were similar between MSH patients on HU and patients registered in the Belgian study. Furthermore, most of the patients are older than 4 years, and above this age, it is well known that the incidence of ACS decreases gradually.19 Nevertheless, prospective studies are mandatory to assess the decreased rate of ACS on HU and the possible reduction in the occurrence of chronic lung disease.4 No patient developed leg ulcers, although an occurrence of 8.5% is found in patients on continuous HU for chronic myelogenous leukemia or other myeloproliferative disorder.20,21 Transfusion requirement is difficult to analyze because some patients, mostly those suffering from stroke or TIA, continued to be on a chronic transfusion program for a few months after starting HU; transfusions were also given to some patients prior to surgery, and the local policy for transfusion during VOC was quite different from center to center. Of interest, 55% of severely affected patients may expect to remain free of VOC at 5 years. The probability to remain free of any event at 5 years was 47%. Furthermore, of the 22 patients who were observed on HU during at least 5 years, the clinical benefit of HU was clearly maintained over the years with fewer hospitalizations, fewer days in the hospital, and fewer VOC or other events. In our experience, HU therapy was safe with no clinically significant hematopoietic depression requiring cessation of drug therapy. Most of the patients were maintained on doses less than 20 to 25 mg/kg per day throughout the entire follow-up without any evidence of loss of efficacy, as assessed by annual hospitalization rate and duration of hospitalization. Increasing doses to reach the maximal tolerated doses was not an usual practice among clinicians who took care of patients with SCD but this attitude did not reduce the clinical efficacy of the drug. No other severe toxicity occurred. Nail, skin, or hair modifications were not prospectively analyzed and, if present, were considered by the physician as a minor event and not reported; the treatment was never stopped by the patient or the physician on the sole basis of these events. Malignancy has been reported in one SCD patient on HU,22 but its incidence may be no higher than in the general population. In our study, no malignancy occurred on HU after a mean 3 years of follow-up, but the question of a possible risk of leukemogenesis in SCD patients on HU can only be answered by long-term follow-up of these patients. We conclude that there is presently evidence that prolonged HU treatment of young patients with SCD appears efficacious, safe, and cost-effective in view of the low cost of the drug and the reduction in both the number of admissions and the number of days of hospitalization.
Submitted August 23, 2000; accepted January 25, 2001.
Supported in part by Grant Télévie 7.4503.96, 7.4511.97, and 7.4510.99 from the Fonds National de la Recherche Scientifique (FNRS), Belgium.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alina Ferster, Hôpital Universitaire des Enfants, Av J J Crocq, 15-1020, Brussels, Belgium; e-mail: esariban{at}ulb.ac.be.
1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. N Engl J Med. 1991;325:11-16[Abstract]. 2. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 1990;27:360-376[Medline] [Order article via Infotrieve].
3.
Platt OS, Brambilla DJ, Rosse WF, et al.
Mortality in sickle cell disease: life expectancy and risk factors for early death.
N Engl J Med.
1994;330:1639-1644 4. Powars D, Weideman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine. 1988;67:66-76[Medline] [Order article via Infotrieve]. 5. Powars D. Sickle cell anemia: beta-S-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol. 1991;28:202-208[Medline] [Order article via Infotrieve].
6.
Charache S, Terrin ML, Moore RD, et al.
Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
N Engl J Med.
1995;332:1317-1322 7. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive "switching" agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine. 1996;75:300-326[CrossRef][Medline] [Order article via Infotrieve].
8.
Ferster A, Vermylen C, Cornu G, et al.
Hydroxyurea for treatment of severe sickle cell anemia : a pediatric clinical trial.
Blood.
1996;88:1960-1964 9. Ohene-Frempong K, Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next? Semin Hematol. 1997;34:30-41[Medline] [Order article via Infotrieve]. 10. Vermylen C, Fernandez-Robles E, Ninane J, Cornu G. Bone marrow transplantation in 5 children with sickle cell anemia. Lancet. 1988;1:1427-1428[Medline] [Order article via Infotrieve]. 11. Ferster A, Devalck C, Azzi N, Fondu P, Toppet M, Sariban E. Bone marrow transplantation for severe sickle cell anemia. Br J Haematol. 1992;80:102-105[Medline] [Order article via Infotrieve]. 12. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: the European experience. Am J Pediatr Hematol Oncol. 1994;16:18-21[Medline] [Order article via Infotrieve]. 13. Vemylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22:1-6[CrossRef][Medline] [Order article via Infotrieve]. 14. De Montalembert M, Belloy M, Bernaudin F, et al. Three year follow-up of hydroxyurea treatment in children with sickle cell disease. The French Study Group on Sickle Cell Disease. Am J Pediatr Heamatol Oncol. 1997;19:313-318.
15.
Kinney TR, Helms RW, O'Branski EE, et al.
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial.
Blood.
1999;94:1550-1554
16.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al.
and the Cooperative Study of Sickle Cell Disease. Cerebrovascular accidents in sickle cell disease: rates and risk factors.
Blood.
1998;91:288-294 17. Pegelow C, Adams RJ, McKie V, Abboud M, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899[CrossRef][Medline] [Order article via Infotrieve].
18.
Ware RE, Zimmerman SA, Schultz WH.
Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
Blood.
1999;94:3022-3026
19.
Castro O, Brambilla DJ, Thorington B, et al.
The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.
Blood.
1994;84:643-649
20.
Best PJ, Daoud MS, Pittelkow MR, Petit RM.
Hydroxyurea-induced leg ulceration in 14 patients.
Ann Intern Med.
1998;128:29-32 21. Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis. 1993;52:217-219[Medline] [Order article via Infotrieve]. 22. Davies SC, Beuzard Y, Borgna-Pignatti C, et al. The effect of hydroxyurea in sickle cell disease: a European registry of benefits and toxicity [abstract]. Haematology. 1999;84:PO-0980.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. J. Strouse, S. Lanzkron, M. C. Beach, C. Haywood, H. Park, C. Witkop, R. F. Wilson, E. B. Bass, and J. B. Segal Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children Pediatrics, December 1, 2008; 122(6): 1332 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lanzkron, J. J. Strouse, R. Wilson, M. C. Beach, C. Haywood, H. Park, C. Witkop, E. B. Bass, and J. B. Segal Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease Ann Intern Med, June 17, 2008; 148(12): 939 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. S. Platt Prevention and Management of Stroke in Sickle Cell Anemia Hematology, January 1, 2006; 2006(1): 54 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Hankins, R. E. Ware, Z. R. Rogers, L. W. Wynn, P. A. Lane, J. P. Scott, and W. C. Wang Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study Blood, October 1, 2005; 106(7): 2269 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gulbis, D. Haberman, D. Dufour, C. Christophe, C. Vermylen, F. Kagambega, F. Corazza, C. Devalck, M.-F. Dresse, K. Hunninck, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience Blood, April 1, 2005; 105(7): 2685 - 2690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M de Montalembert, C Maunoury, P Acar, V Brousse, D Sidi, and G Lenoir Myocardial ischaemia in children with sickle cell disease Arch. Dis. Child., April 1, 2004; 89(4): 359 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Zimmerman, W. H. Schultz, J. S. Davis, C. V. Pickens, N. A. Mortier, T. A. Howard, and R. E. Ware Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease Blood, March 15, 2004; 103(6): 2039 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Wilson, L. Krishnamurti, and D. Kamat Management of Sickle Cell Disease in Primary Care Clinical Pediatrics, November 1, 2003; 42(9): 753 - 761. [PDF]
|
|
|
|
 |
|
 M. H. Steinberg, F. Barton, O. Castro, C. H. Pegelow, S. K. Ballas, A. Kutlar, E. Orringer, R. Bellevue, N. Olivieri, J. Eckman, et al. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment JAMA, April 2, 2003; 289(13): 1645 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Venigalla, B. Motwani, A. Nallari, S. Allen, M. Agarwal, M. Alva, M. Westerman, and L. Feldman A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection Blood, June 17, 2002; 100(1): 363 - 364. [Full Text] [PDF]
|
|
|
|
|
|
M. de Montalembert and S. C. Davies Is hydroxyurea leukemogenic in children with sickle cell disease? Blood, November 1, 2001; 98(9): 2878 - 2879. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, K. Ohene-Frempong, and W. Wang Sickle Cell and the Brain Hematology, January 1, 2001; 2001(1): 31 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Hankins, R. E. Ware, Z. R. Rogers, L. W. Wynn, P. A. Lane, J. P. Scott, and W. C. Wang Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study Blood, October 1, 2005; 106(7): 2269 - 2275. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
.05). Again
the McNemar test for a difference between the occurrences of VOC or the
occurrence of an event in the year before start of HU and at the end of
the first year of treatment showed a significant difference
(P = .001); the occurrence of VOC requiring
hospitalization or an event was lower after the first year of
treatment. The estimated time to the occurrence of VOC among patients
receiving HU is shown in Figure 
